/
We are a biopharmaceutical company with a mission of pioneering medicines that transform patients lives. We are devoting most of our resources to the research and development of our most advanced drug candidates and the commercialization of our approved drug, INPEFA (sotagliflozin): We are developing sotagliflozin, an orally-delivered small molecule drug candidate, as a treatment for hypertroph…
The business is unprofitable at the operating level (-98.21% margin). The thesis depends entirely on whether and when it reaches sustainable profitability.
Revenue up 60.2% YoY with margins expanding 536.0pp.
Negative free cash flow of -$68M. The business is consuming cash, not generating it.
Profitability & Returns
Revenue (TTM)
$70M
▲ +60.2% YoY
Net Income (TTM)
-$26M
▲ +74.9% YoY
Op. Margin
-34.79%
▲ +536.0pp YoY
ROIC
-9.49%
▲ +50.7pp YoY
Cash Flow & Balance Sheet
FCF (TTM)
-$39M
▲ +62.3% YoY
Op. Cash Flow (TTM)
-$39M
▲ +62.0% YoY
Net Debt
-$113M
Net Cash Position
Cash & Equiv.
$171M
5Y CAGR: +15.7%
Continue Research